PMID- 22291820
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 1896-9151 (Electronic)
IS  - 1734-1922 (Print)
IS  - 1734-1922 (Linking)
VI  - 7
IP  - 5
DP  - 2011 Oct
TI  - Effectiveness and tolerability of ezetimibe co-administered with statins versus 
      statin dose-doubling in high-risk patients with persistent hyperlipidemia: The 
      EZE(STAT)2 trial.
PG  - 767-75
LID - 10.5114/aoms.2011.25550 [doi]
AB  - INTRODUCTION: When a standard dose of statins fails to achieve lipid control in 
      patients at high risk for coronary artery disease (CAD), increasing the statin 
      dosage or co-administration of additional agents is recommended. The aim of this 
      study was to compare the safety and lipid-lowering efficacy of doubling the 
      standard statin dose (STAT2) to that of co-administering ezetimibe 10 mg/day 
      (EZE+statin) in Canadian patients at high CAD risk with persistent hyperlipidemia 
      upon statin treatment. MATERIAL AND METHODS: Six-week, open-label, randomized, 
      multicentre study. The primary outcome was the change in plasma LDL-C and 
      secondary measures included the change in additional lipid parameters. Safety was 
      assessed with the incidence of emergent adverse events (AEs). RESULTS: Eight 
      hundred eighty-five patients (EZE+statin, n=586; STAT2, n=299) completed the 
      study. The mean (SD) percent change in low-density lipoprotein cholesterol 
      (LDL-C) was - 30.9% (18.2) for the EZE+statin group and -18.4% (19.0) for the 
      STAT2 group (p=0.001). Percent and absolute decreases in total cholesterol (TC), 
      triglycerides and the TC to high-density lipoprotein cholesterol ratio (TC/HDL-C) 
      were significantly greater for the EZE+statin group (p = 0.001). After 6 weeks of 
      treatment, 70% of the patients in the EZE+statin group and 48% of patients in the 
      STAT2 group (OR=2.45, p<0.001) achieved target LDL-C levels of<2.5 mmol/l. 
      Incidence of AEs was similar between groups, with the exception of a higher 
      incidence of muscle disorders in the STAT2 group. CONCLUSIONS: In patients at 
      high CAD risk who are above the LDL-C target while on statin monotherapy, 
      co-administration of ezetimibe is well tolerated and more effective in improving 
      the lipid profile compared to doubling the existing statin dose.
FAU - Shekhar Pandey, A
AU  - Shekhar Pandey A
AD  - Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada.
FAU - Bissonnette, Stephane
AU  - Bissonnette S
FAU - Boukas, Stella
AU  - Boukas S
FAU - Rampakakis, Emmanouil
AU  - Rampakakis E
FAU - Sampalis, John S
AU  - Sampalis JS
LA  - eng
PT  - Journal Article
DEP - 20111108
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC3258811
OTO - NOTNLM
OT  - ezetimibe
OT  - hypercholesterolemia
OT  - low-density lipoprotein cholesterol
OT  - statin
EDAT- 2012/02/01 06:00
MHDA- 2012/02/01 06:01
PMCR- 2011/12/01
CRDT- 2012/02/01 06:00
PHST- 2010/07/20 00:00 [received]
PHST- 2010/11/20 00:00 [revised]
PHST- 2010/12/28 00:00 [accepted]
PHST- 2012/02/01 06:00 [entrez]
PHST- 2012/02/01 06:00 [pubmed]
PHST- 2012/02/01 06:01 [medline]
PHST- 2011/12/01 00:00 [pmc-release]
AID - 17609 [pii]
AID - 10.5114/aoms.2011.25550 [doi]
PST - ppublish
SO  - Arch Med Sci. 2011 Oct;7(5):767-75. doi: 10.5114/aoms.2011.25550. Epub 2011 Nov 
      8.